About 30%-50% cases of neuropathy are refractory to standard treatment options used (Nortriptyline, Gabapentin, Pregabalin, Duloxetine etc). Adding Nucleopalm to the standard care in patients with mild to moderate refractory neuropathy is shown to provide additional reduction in mean TSS, mean MNSI & mean NPSI scores
Effect of Nucleopalm on diabetic painful neuropathy evaluated by Michigan Neuropathy Screening Instrument (MNSI), Total Symptom Score (TSS), and Neuropathic Pain Symptoms Inventory (NPSI). ANOVA shows a significantly decreased pain intensity and symptom scores were observed by MNSI, TSS, and NPSI (P < 0.0001) during the treatment period and compared to baseline.
Effect of Nucleopalm on each single neuropathic pain symptom assessed by Total Symptom Score (TSS). The intensity and frequency of pain, burning, paresthesia, and numbness, evaluated by TSS, show a significant mitigation (P < 0.0001) after 60 days of treatment compared to baseline. This effect persists even one month after treatment discontinuation.
Effects of Nucleopalm on single subcategories of neuropathic pain symptoms measured by Neuropathic Pain Symptoms Inventory (NPSI). ANOVA confirmed the significant improvement, compared to baseline (P < 0.0001), of the more important characteristics of neuropathic pain: spontaneous superficial burning pain, deep spontaneous pressing pain, paroxysmal pain, paresthesia /dysesthesia and evoked pain evaluated by NPSI.
Reduction in number of positive tender points. Retrospective group (circle with continuous line): patients received DLX + PGB from baseline to sixth month. Number of TPS reduction was statistically significant < 0.05. Prospective group (square with continuous line): patients received DLX + PGB from baseline to third month. Nucleopalm was added to DLX + PGB (square with discontinuous line) fiom third to sixth month. Number of TPS reduction was statistically significant <0.0001.
Reduction in pain intensity by VAS measurement. Retrospective group (circle with continuous line): patients received DLX + PGB from baseline to sixth month. VAS reduction was statistically significant < 0.05. Prospective group (square with continuous line): patients received DLX + PGB from baseline to third month. Nucleopalm was added to DLX + PGB (square with discontinuous line) from third to sixth month. VAS reduction was statistically significant < 0.0001.
